Not yet recruiting NCT06932861

Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma

Early Phase I Interventional Rhabdomyosarcoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied: The protocol lists: mRNA Tumor Vaccine Therapy.
Who it may be relevant to: Registry conditions: Rhabdomyosarcoma. Basic parameters: from 6 years · All.
What needs checking: Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place: Center list to be confirmed — check the primary protocol.
Next step: Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

An Exploratory Study on the Use of mRNA Tumor Vaccines in the Treatment of Refractory Rhabdomyosarcoma

Adverse Event [Time frame: From the first administration of the study drug until the occurrence of death, loss to follow-up, withdrawal of informed consent, initiation of a new anti-tumor therapy, or 21 days after the last dose, whichever comes first.]

Diagnosed with rhabdomyosarcoma confirmed by pathological or molecular testing;
Age ≥ 6 years;
No known effective treatment available or no treatment proven to prolong survival with an acceptable quality of life;
Expected survival time greater than 6 months;
ECOG performance status score of 0-1; -

1.History of or concurrent with other untreated malignant tumors, except for previously cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and superficial bladder cancer; 2.History of or current active autoimmune diseases. 3.Has uncontrolled cardiovascular diseases.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Center list to be confirmed — check the primary protocol.

NCT: NCT06932861 · PRRR Study